选择的抗氧化剂和蛋白酶基因之间的高阶单核酸多态相互作用影响北印度人患慢性阻塞性肺病 (COPD) 和肺功能参数的倾向
Heena Kansal1, Vishal Chopra2, Kranti Garg2
1Department of Biotechnology, Thapar Institute of Engineering & Technology, Patiala, 147004, Punjab, India.
这项研究表明,SOD2,CAT和ADAM33中的特定基因变异相互作用,影响慢性阻塞性肺病 (COPD) 风险和肺功能. 这些发现突显了使用组合遗传特征来个性化治疗COPD的潜力.
科学领域:
- 遗传学和基因组学 遗传学和基因组学
- 肺部医学 肺部医学
- 分子生物学分子生物学
背景情况:
- 慢性阻塞性肺病 (COPD) 的特点是持续的空气流量限制,氧化应激和炎症.
- 像MMP9,MMP12和ADAM33这样的关键蛋白质,以及抗氧化酶 (氨酸过氧化酶,超氧化离氧化酶,catalase),对于肺部平衡至关重要;失衡会增加COPD风险.
研究的目的:
- 研究与COPD风险和临床表型相关的选择抗氧化剂和蛋白酶基因单核酸多态 (SNP) 之间的基因-基因相互作用.
- 为了确定预测COPD易感性和影响肺功能的特定遗传特征.
主要方法:
- 一个病例控制研究,涉及500名健康对照和500名COPD患者.
- 在CAT,SOD1,SOD2,GPx,MMP9,MMP12和ADAM33基因中SNP的基因定型.
- 应用多因素缩小维度 (MDR),分类和回归树 (CART) 和后勤回归来分析基因相互作用和临床数据.
主要成果:
- 确定的SNP (SOD2 rs4880,CAT rs1001179,MMP9 rs17576,ADAM33 rs612709) 与COPD风险的增加有关.
- 已证明高阶基因相互作用,例如SOD2 rs4880与ADAM33 rs612709,影响COPD风险.
- 在肺功能测试 (FEV1,FVC) 和支气管扩展剂反应中观察到基因型特异性差异,某些组合 (例如SOD2,ADAM33,MMP9) 显著改变了结果.
结论:
- 这项研究首次证明了抗氧化剂和蛋白酶基因变异 (特别是SOD2 rs4880,CAT rs1001179,ADAM33 rs612709) 影响COPD风险和肺功能之间的高阶相互作用.
- 这些发现支持组合基因分析对COPD风险分层和个性化治疗策略的开发的有用性.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
14:48Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
Published on: March 21, 2021
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Single Nucleotide Polymorphisms-SNPs
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
